/
Other
Liver
36
Pipeline Programs↗
73
Active Trials↗
41
Companies Involved↗
Liver is a moderately active landscape with 36 programs across 41 companies. The most active players are Gilead, GSK, Eli Lilly. 11 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical13
Phase 17
Phase 25
Phase 311
Approved
No programs
Analysis
Modality Breakdown
94%
Small molecule
31 of 33 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 33 classified programs, each share of the total. Modality classified for 97% of 36 pipeline programs.
Analysis
Trial Status
215
clinical trials
Completed109 · 51%
Recruiting37 · 17%
Not yet recruiting18 · 8%
Active, not recruiting14 · 7%
Unknown status13 · 6%
Terminated11 · 5%
Other13 · 6%
Clinical Trials
Trial Activity
215 trials
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus (CTOT-43)
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT06280950·340 enrolled
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates (CTOT-44)
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT06075745·416 enrolled
Page 1 of 15
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)